Vision / opinion / people
TheSocialMedwork: equal access to medicines for everyone, everywhere
We recently sat down with Sjaak Vink, the visionary entrepreneur behind TheSocialMedwork. This enterprise gives patients all over the world […] May 5, 2020 · BioVox
Why everyone needs to be a part of the CRISPR conversation
With the soaring cost of drugs for rare indications, many biotech and pharmaceutical companies are focusing R&D efforts on orphan diseases. Will the pendulum swing back towards more common maladies? February 26, 2020 · BioVox
Belgian initiatives boosting animal-free innovation
Animals have been used throughout history to understand human physiology and to resolve scientific questions related to health and disease. Nowadays, however, both scientists [...] February 26, 2020 · BioVox
Predictions for Belgian Biotech in 2020
With the Belgian biotech landscape blooming, BioVox reached out to some of the investors in our network to see what their predictions are for the coming year. From trends to companies to keep an eye on, here’s their take on 2020! January 22, 2020 · BioVox
How business models shaped our current drug development trends
With the soaring cost of drugs for rare indications, many biotech and pharmaceutical companies are focusing R&D efforts on orphan […] December 17, 2019 · V-Bio Ventures
Magic mushrooms in modern medicine
More than 75 years after the initial discovery of lysergic acid diethylamide (LSD), psilocybin and other natural psychoactive drugs, and […] November 26, 2019 · V-Bio Ventures
The 2019 Nobel Prize in Medicine: How do cells adapt to changing oxygen levels?
The 2019 Nobel Prize in Physiology or Medicine was awarded to William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza. Their discoveries have [...] October 24, 2019 · BioVox
A bridge from east to west: linking Chinese investors with European companies
There are two main reasons why a European company might want to establish official links with a Chinese investor: funding, […] October 24, 2019 · Turnstone CommunicationsProf. Matthias Mann joins PharmaFluidics Advisory Board
Ghent, Belgium – October 22, 2019 – PharmaFluidics NV, an innovative player in the field of proteomics with the unique high-resolution µPACTM micro-Chip chromatography products, is pleased to welcome Prof. Dr. Matthias Mann as member of its Advisory Board. October 22, 2019 · Turnstone Communications
Closing the gender gap in biotech funding: a follow-up study
In this follow-up to a previous VC Views article, V-Bio Ventures takes a look at several questions that were generated […] September 24, 2019 · V-Bio Ventures
Three business strategy tips to help your company grow
Turnstone Communications, the driving force behind BioVox news, is a consultancy agency catering to life sciences companies. Lending a hand […] September 23, 2019 · BioVox
Fresh insights into the future of cell therapy
The first edition of Science for health was held in the heart of Brussels on September 11 with a focus […] September 23, 2019 · BioVoxGalapagos-Gilead billion-dollar deal: beyond the numbers
Last month, Galapagos sealed a 5-billion-dollar deal with Gilead. Now that the dust has started to settle, we’re taking a […] August 27, 2019 · BioVox
Why events are important for creating connections in the life sciences
Collaboration is vital for science. Without cross-pollination of ideas and talent, progress would be excruciatingly slow in both industry and academia. [...] August 27, 2019 · BioVox
Meet the men who unraveled the mystery of protein folding
Franz-Ulrich Hartl and Arthur Horwich have been named the winners of the 2019 Dr. Paul Janssen Award for Biomedical Research. […] August 27, 2019 · Janssen Pharmaceutica
How do we reduce the high cost of clinical trials?
Drug development is an exorbitantly expensive endeavor. A large expense factor for developing a new therapy is the high cost of conducting clinical trials. [...] July 18, 2019 · V-Bio Ventures
Living on the edge: the challenge of doing things differently in cell therapy
Belgian company Celyad is a trailblazer in oncology: its T cell therapies based on NK receptors are cutting edge even […] July 17, 2019 · BioVox
The future of healthcare is digital
This month marked the crystal anniversary of the life sciences networking event Knowledge for Growth. The event was a huge […] May 29, 2019 · Turnstone Communications
OCTIMET Oncology tackling cancer with a new captain at the helm
In this VC Views article, V-Bio Ventures introduces one of their portfolio companies, OCTIMET. This Belgian oncology startup just added […] May 29, 2019 · V-Bio Ventures
Science for health: a new event for creating research connections
Science for health is Belgium’s new research event, set to promote more collaborations in our stellar life sciences ecosystem. The […] May 29, 2019 · BioVox
Closing the gender gap in biotech funding
Companies with a good gender balance consistently outperform those with only men in their management teams. Yet despite this, start-ups […] March 19, 2019 · V-Bio Ventures
Women in STEM: fixing the leaky pipeline
Happy International Women’s Day! This year, in honor of the day, we’ve decided to highlight an important and personal topic: […] March 8, 2019 · BioVox
Orphan CNS diseases receive attention with new Minoryx site in Belgium
The Spanish start-up Minoryx Therapeutics recently opened a subsidiary in Belgium to further their research on treatments for rare and […] March 4, 2019 · BioVox
Life after a PhD: alternatives to academia
Having finished a PhD in life sciences can often leave you wondering: what’s next? The classic question is often “academia […] February 19, 2019 · V-Bio Ventures
From scientist to entrepreneur: how a Belgian chromatography company came to be
Pharmafluidics is a Belgian company rethinking the fundamentals of liquid chromatography. Introducing a fundamentally new type of stationary phase in […] February 12, 2019 · Turnstone Communications
Are we spending too much money on cancer drugs?
November is classically the month where immunotherapy takes center stage, especially at the annual conference of the Society for Immunotherapy […] January 22, 2019 · V-Bio Ventures
argenx signs billion-dollar deal with Janssen
Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody […] December 4, 2018 · Turnstone Communications
A Personal Translation of Microbiome Futures
Nature Biotechnology published a thought-provoking piece addressing critical questions in the development of microbiome-based solutions focused on disease interception. Co-authored […] November 28, 2018 · Janssen Pharmaceutica
Why start-ups can become mega companies in the pharma sector
In a previous BioVox article, we analyzed the steps needed for a life sciences start-up to turn into a fully […] November 20, 2018 · V-Bio Ventures
Microbiome regulations from an EU start-up's perspective
Interested in the microbiome? So are we! Here’s a sneak-peek into S-Biomedic, one of the first microbiome start-ups in Belgium. […] November 9, 2018 · Turnstone Communications
The Benefit of BioVox – why science journalism matters
This year, for the third time in a row, the BioVox team is looking forward to attending Wallonia’s largest life […] November 7, 2018 · BioVox
AI and The Black Box Dilemma
Artificial intelligence has become a regular staple in our modern lives. With increasingly complex programs allowing for scarily accurate image […] November 6, 2018 · BioVox
Are tech investments under threat by anti-science sentiments?
In biotech, company creation is usually preceded by scientific discoveries presenting solutions to existing problems. Because of this, early stage […] October 30, 2018 · V-Bio Ventures
Ghent knowledge hub growing strong
The Flemish life sciences ecosystem is stronger than ever. This expertise, in biotech and health, is plain to see in […] October 23, 2018 · Turnstone Communications
Lessons in Herding Cats: Business Development for Life Sciences Companies
Business development challenges can make or break a company in any industry. For a life sciences company, overcoming the added […] October 16, 2018 · Janssen Pharmaceutica
What’s next for CRISPR crops in the EU?
Genetically Modification Organisms (GMOs) is one of the most hotly debated topics in the news today. Resistance to GMOs has […] October 9, 2018 · BioVox
Bringing clinical trials into the home
Lowering the costs of drug development is more important than ever; with the increasing pressure on drug pricing and billions […] October 2, 2018 · V-Bio Ventures
Are the days of journal paywalls finally numbered?
Europe has taken an ambitious step forwards in the fight for open access to academic papers. On September 4th, Science […] September 25, 2018 · BioVox
Saving lives through fundamental research: James Allison wins Dr. Paul Janssen Award 2018
Dr. James Allison has dedicated his career to improving our fundamental understanding of how the adaptive immune system works. Much […] September 18, 2018 · Janssen Pharmaceutica
Forever young: the science of aging well
“Is aging a disease?” For a long time, the answer to this question seemed obvious: aging is a natural thing […] August 28, 2018 · V-Bio Ventures
Uncovering the secrets of inflammasomes
Mohamed (Mo) Lamkanfi made the jump from academia to industry a mere eight months ago, to pursue a career with […] August 21, 2018 · Janssen Pharmaceutica
Biotechs and subsidies - a fraught relationship
The ambition of any CEO heading a biotech start-up is to develop a new product and to reach patients quickly. […] July 23, 2018 · V-Bio Ventures
1 billion lifeforms recorded!
The Global Biodiversity Information Facility (GBIF) is an international network that provides access to a huge biodiversity database. Their total […] July 10, 2018 · BioVox
Damya Laoui at the forefront of cancer immunotherapy
Photo copyright: VUB / Thierry Geenen Last year, Damya Laoui received the prestigious American MIT-prize for young innovators under 35 […] July 3, 2018 · BioVox
DNA as a storage device for big data
Sometimes science fiction seems to become real right in front of our eyes. Slowly but surely, our genes are revealing […] June 19, 2018 · BioVox
CD3 as co-creator of drugs with academia and pharma
The Center for Drug Design and Discovery (CD3), based in Leuven, bridges the gap between innovative biomedical research emerging from […] May 28, 2018 · Turnstone Communications
Acquisitions of Biotech companies: a good or a bad thing?
When on the 8th January 2018 the news travelled that Novo Nordisk made a €2.6bn bid for Belgium’s Ablynx, only […] May 14, 2018 · V-Bio Ventures
How to build a “European Amgen”
There are still very few large European biotech companies to compete with the Amgens and Gileads of the world. Only […] April 19, 2018 · V-Bio Ventures
Big data, big produce – Trends in agri-biotech
In the last few decades, with the introduction of GMOs, the agricultural industry was turned upside down. Major consolidations between […] April 16, 2018 · BioVox
From Academia to Industry: growing in new directions
What does it mean to “be a scientist”? People generally have a very academia-centric view: scientists do research, write grants […] April 12, 2018 · Janssen Pharmaceutica
A world without disease: Janssen - Flanders.bio partner day 2018
A new vision was in the spotlight at the Flanders.bio – Janssen Pharmaceutica Partner Day this year. “A world without […] March 19, 2018 · Janssen Pharmaceutica
Is innovation killing the pharmaceutical industry?
In the past few years, the speed at which new drugs have been coming to the market has accelerated significantly […] March 18, 2018 · V-Bio Ventures
Caitlin Gillis at VIB - Foreign Scientist in Belgium
Caitlin Gillis left the sunshine and warmth of Australia a few years ago to come live Europe. After a stint […] March 18, 2018 · BioVox
After Ablynx, is an acquisition of Galapagos next?
The Gent biotech company Ablynx has been acquired by pharmaceutical giant Sanofi for 3.9 billion euros. The French Sanofi beat […] February 19, 2018 · BioVox
Politicians should consider the consequences of not deploying GM technology
Genetic modification (GM) technology can offer solutions so that farmers can more efficiently grow crops with less environmental impact. Despite […] February 19, 2018 · BioVox
Artificial intelligence beyond the hype: achievements and expectations in the biotech space
Artificial intelligence (AI) is a term that pops up everywhere lately. In this article, we provide some examples of how […] January 18, 2018 · V-Bio Ventures
Olivier Gevaert in Stanford – Belgian scientist living abroad
After an Erasmus exchange in Germany during his Master’s in Industrial Engineering, Olivier Gevaert knew he would someday move abroad. […] December 18, 2017 · BioVox
Synthetic biology – revolutionary technology in search of a better name
Despite what the name might suggest, synthetic biology is not about creating artificial life. Instead, it focuses on scouring nature […] December 18, 2017 · Turnstone Communications
Interactomics: taking apart the cellular machinery
Among the booming omics disciplines, such as genomics, proteomics, or metabolomics, the field of interactomics is perhaps less known. VIB […] November 21, 2017 · BioVox
Belgium vs Germany in the Life Sciences start-up championship
Germany is one of the leading industrial nations in the world and has 8x more inhabitants than Belgium. However, when […] November 20, 2017 · V-Bio Ventures
Diagnosed with lung cancer
A patient diagnosed with lung cancer should brace for the worst. Prognosis is often very disappointing. While in many cancers […] October 16, 2017 · Turnstone Communications
Tackling untreatable cancers in children
Bram De Wilde is a pediatric hemato-oncologist at the University Hospital in Ghent. He is one of the keynote speakers […] October 16, 2017 · Turnstone Communications
How Aphea.Bio managed to gather the funds to transcend from academia to industry
Aphea.Bio is an agriculture startup, originating from the VIB and flourishing underneath the wings of V-Bio Ventures. Steven Vandenabeele (CTO […] October 16, 2017 · V-Bio Ventures
Liesbeth Aerts in Sydney - Belgian scientist living abroad
Until August 2017, Liesbeth Aerts lived in Sydney, where she worked as a dementia researcher at the University of New […] October 9, 2017 · BioVox
Personalized healthcare, a long-awaited revolution
Although it’s already 2017 and medicine has made great progress in the last decade, healthcare is often still very generic, […] September 11, 2017 · Turnstone Communications
The leap from academia to industry
The earlier in development, the greater the risk. It’s an unspoken law in biotech that makes valorizing promising academic projects […] September 11, 2017 · V-Bio Ventures
Lars Klareskog pushes rheumatology beyond symptomatic treatment
Over the years, the perception of inflammatory diseases has changed drastically. The advent of cytokine inhibitors meant great improvement to many patients, especially those suffering from rheumatoid arthritis. However, these treatments remain symptomatic. Together with Janssen Pharmaceutica, world-renowned rheumatologist Lars Klareskog is ready to take the research and treatment of inflammatory joint disease to the next level.
June 12, 2017 · Janssen Pharmaceutica
Sylvie Janssen in Manhattan - Belgian scientist living abroad
Sylvie Janssens lives in Manhattan, New York, where she relocated after earning her PhD in biotechnology at Ghent University. She […] June 8, 2017 · BioVox
Strengthening communication in biotech companies
Many biotech management teams fail to reach out to investors in a clear and appealing way.
May 22, 2017 · V-Bio Ventures
Janssen R&D focus enforced with new managing director
Stef Heylen is the new Managing Director and COO of Janssen Pharmaceutica (Belgium), since November 2016. After a half year […] May 22, 2017 · Janssen Pharmaceutica
Curing all diseases in the next 20 years: the new hype amongst billionaires?
Despite the initial intent of charitable foundations to be not-for-profit, some of them tend to morph into organizations with bigger aspirations.
April 17, 2017 · V-Bio Ventures
CMAST: Bringing ideas from a risky early stage to a viable healthcare solution
CMAST knows that much more than good science is needed to create innovative healthcare solutions that will have an impact […] April 14, 2017 · Turnstone Communications
Investing in European biotech faced with many challenges
Investing in biotech companies is a capital-intensive and risky business, and it’s no secret that more money and less risk-averse investors are available in the US than in Europe. To keep innovations, companies, and their economic benefits from being transferred to regions outside Europe, many national and international European initiatives are in place. The question remains whether this is sufficient to fundamentally improve Europe’s currently underfunded biotech ecosystem. The biotech investment specialists of V-Bio Ventures take us through Europe’s biotech investment landscape.
March 16, 2017 · V-Bio Ventures
Your body modeled in a computer?
The Virtual Physiological Human (VPH) is a fantastic, noble concept first discussed in Europe in the late nineties. The initiative sought to develop a detailed [...] March 13, 2017 · Turnstone Communications
Connecting science and citizens
The ways people are conducting bioscience are changing. Cheaper equipment has paved the way for citizens to perform increasingly advanced […] February 13, 2017 · BioVox
Market Access – the pitfall where innovations go lost
Market access is a crucial turning point for many companies. Getting your drug reimbursed by the government means the world. However, gaining market access [...] January 17, 2017 · Turnstone Communications
Better together: R&D and GMP analytics teamed up at anaRIC Biologics
Biologics are conquering the medical space. The need for high-quality analytical service companies for biological products has never been bigger. […] January 17, 2017 · Turnstone Communications
Flanders Innovation and Enterpreneurship hands out over 500 million euros
Startup companies can get funding from the Flemish government for their R&D activities. Recently, the responsible agency was reformed and […] December 13, 2016 · Turnstone Communications
V-Bio Ventures spends big money in life sciences
Only one year after its inception, the life science investment fund V-Bio Ventures made its first investments in three companies and announced the final closing [...] December 13, 2016 · V-Bio Ventures
Confo Therapeutics: Drugging the Undruggable
Llama single-domain antibodies have found yet another application, one that Confo Therapeutics is fully exploiting. Ablynx is developing Nanobodies®, AgroSavfe […] December 13, 2016 · V-Bio Ventures
Biotech through the eyes of a financial analyst
Ward Capoen studied biology and subsequently obtained a PhD in biotechnology at Ghent University. He worked as a postdoctoral fellow […] December 9, 2016 · V-Bio Ventures
Inside a life sciences fund: V-Bio Ventures
V-Bio Ventures, the new Belgian fund for life sciences startups, is currently being managed by Christina Takke and Willem Broekaert. […] December 7, 2016 · V-Bio Ventures
Music or neuroscience? Balthazar’s violinist chose music (at least for now)
For Patricia Vanneste, violinist with the popular rock group Balthazar, it wasn’t a choice she made lightly. Patricia has played the violin since she was five. [...] December 6, 2016 · BioVox
Second and third lives for known cancer drugs
While development of new cancer treatments is ongoing, innovators are also trying to further optimize the use of known cancer […] November 15, 2016 · Turnstone Communications
Life sciences high on the UGent priority list
Interdisciplinary research is a top priority for Anne De Paepe, Chancellor of Ghent University in Belgium. Even if it means […] November 15, 2016 · Turnstone Communications
Biotech financials: Part 2 — the Belgian stock market
Biotech is a sector that involves considerable risk: The amount of capital required is huge, and any clinical research program […] November 14, 2016 · BioVox
A new level of science: artificial evolution and complex systems
Pierre Collet, professor in Computer Science at Strasbourg University, is one of the key opinion speakers at the BioWin Day 2016. He works on artificial evolution, [...] October 27, 2016 · Turnstone Communications
Wallonia’s life sciences cluster is bursting with activity
BioWin is Wallonia’s competitiveness cluster (pôle de compétivité) for life sciences. You could also consider it as the FlandersBio of […] October 24, 2016 · Turnstone Communications
Protect your intellectual property!
Do you want to start up a biotech company or secure additional financing? Nice! Do you have a great technology […] October 24, 2016 · Turnstone Communications
ADHD, a disorder cured by play
In 2013, a new BioWin project, NeuroAtt, was launched to arrive at a reliable diagnosis for ADHD (Attention Deficit Hyperactivity Disorder) and to find the least [...] October 14, 2016 · Turnstone Communications
First “three-parent baby” born
Mutations in mitochondrial DNA can cause severe diseases and fertility problems. Since mitochondria are only inherited from the mother, a mother with faulty [...] October 14, 2016 · BioVox
Jeroen Pollet in Texas - Belgian scientist living abroad
Houston (Texas, USA) has been home to Jeroen Pollet since August 2011. He arrived as a Fulbright scholar; now he is an assistant professor at Baylor College of Medicine (BCM) [...] October 14, 2016 · BioVox
Why Nobel laureates are condemning Greenpeace’s anti-GMO campaign
Genetically modified crops are grown by 18 million farmers in 28 countries worldwide. In May, a federal study by the […] September 13, 2016 · BioVox
Biotech financials: Part 1 - The bigger the company, the bigger the money
Belgium is internationally known for its flourishing biotech scene. Companies such as Galapagos and Ablynx are now synonymous with innovation […] September 12, 2016 · BioVox
Lifting life sciences to the next level: a cross-disciplinary game
We at BioVox have mentioned the golden rules for life sciences success a couple times now: “Collaboration is key” and […] September 12, 2016 · Turnstone Communications
The power of big data constricted by law?
Huge amounts of data, including personal data, are currently being created. If we are to believe IBM, 90% of the […] September 12, 2016 · Janssen Pharmaceutica
The PhD of Sue Ellen : Start small to dream big
Sue Ellen Taelman studied bioscience engineering (with an emphasis on environmental technology ) at Ghent University from 2007 until 2012. […] September 12, 2016 · Turnstone Communications
One year of BioVox! How did we do?
In May 2015, BioVox went live. During this first year, we created over 100 original articles covering the Belgian healthcare […] August 9, 2016 · BioVox